生命科学资讯
生物技术与制药领域的最新动态
龙沙集团(VTX:LONN)一年内45%的盈利增长未能转化为股东收益——雅虎财经
45% earnings growth over 1 year has not materialized into gains for Lonza Group (VTX:LONN) shareholders over that period - Yahoo Finance
财报电话会议纪要：龙沙集团2025年第四季度业绩未达预期，股价下跌9% - Investing.com
Earnings call transcript: Lonza misses Q4 2025 forecasts, stock drops 9% - Investing.com
德意志银行维持对龙沙集团（LZAGY）2026年2月“买入”评级 - 迈卡
Deutsche Bank Maintains Buy on Lonza Group AG (LZAGY) Feb 2026 - Meyka
合同制药商龙沙预测2026年销售增长放缓 - MSN
Contract drug manufacturer Lonza forecasts slower sales growth for 2026 - MSN
龙沙集团：默默驱动下一波生物科技浪潮的隐形引擎 - 特别报道
Lonza Group AG: The Silent Engine Powering the Next Wave of Biotech - AD HOC NEWS
瑞士合同制药商龙沙预测2026年销售增长将放缓——MSN报道
Contract drug manufacturer Lonza forecasts slower sales growth for 2026 - MSN
CDMO占据新闻头条——龙沙传递出明确的实力信号 - 欧洲生物技术杂志
CDMOs dominate the headlines – and Lonza delivers a clear message of strength - European Biotechnology Magazine
龙沙集团销售额因新合同势头而增长 - MSN
Lonza sales grow on new contract momentum - MSN
龙沙集团2025年业绩强劲增长 - thereporter.com
Lonza reports strong growth in 2025 - thereporter.com
龙沙集团持续利用生物制药优化趋势（场外交易代码：LZAGY）——Seeking Alpha
Lonza Group Continues To Leverage Biopharma’s Optimization Push (OTCMKTS:LZAGY) - Seeking Alpha
'永不止步'：新业主如何重塑前基因泰克基地的辉煌——商业期刊报道
'We don't stop': How a new owner is turning around a former Genentech site - The Business Journals
龙沙集团确定2026年普通股东大会召开日期 - TipRanks
Lonza Sets Date for 2026 Ordinary General Meeting - TipRanks
龙沙集团胶囊业务出售谈判接近尾声——Finimize报道
Lonza’s Capsules Sale Talks Are Nearing The Finish Line - Finimize
晨星：窄护城河龙沙长期前景受强劲外包药物制造需求驱动
Narrow-Moat Lonza's Long-Term Outlook Driven by Strong Outsourced Drug Manufacturing Demand - Morningstar
瑞士龙沙集团接近出售其胶囊与健康成分业务
Switzerland’s Lonza edges closer to sale of its capsule and health ingredients business - 93.3 The Drive
龙沙集团仍计划出售其胶囊与健康成分业务——Endpoints新闻
Lonza still intends to sell its capsules and health ingredients business - Endpoints News
财报电话会议记录：龙沙集团公布2025年强劲业绩，股价却小幅下跌 - Investing.com
Earnings call transcript: Lonza reports strong 2025 results, stock dips - Investing.com
Lonza预计2025年强劲增长后，2026年将保持稳定增长——Finimize
Lonza Sees Steady 2026 Growth After A Strong 2025 - Finimize
瑞士龙沙集团接近出售其胶囊与健康配料业务——路透社
Switzerland's Lonza edges closer to sale of its capsule and health ingredients business - Reuters